Bolt Biotherapeutics to Participate in Upcoming Conferences
Key Highlights
- ➤Bolt schedules presentations at Stifel and Jefferies healthcare conferences
- ➤October acquisition of Prana included $120 million private placement financing
- ➤Warrants could provide up to an additional $60 million
- ➤PRA-216 advances in Phase 2 across multiple inflammatory diseases
REDWOOD CITY, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) (“Bolt” or the “Company”), a clinical-stage biotechnology company pioneering a new generation of half-life-extended multispecific antibodies designed to deliver best-in-disease therapies, today announced participation in two upcoming investor conferences.
Sheila Gujrathi, M.D., Chief Strategy Officer of Bolt and Co-Founder and former Chief Executive Officer of Prana Therapies, will deliver a company presentation, followed by a fireside chat, on Tuesday, November 10, 2026, at 10:40 a.m. ET at the Stifel 2026 Healthcare Conference, and attend Jefferies Global Healthcare Conference in London, taking place November 16–19, 2026.
Get started
Create a free account to read the full story.